EE372 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative Advanced/Metastatic Breast Cancer in Colombia
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.620
https://www.valueinhealthjournal.com/article/S1098-3015(22)00821-X/fulltext
Title :
EE372 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative Advanced/Metastatic Breast Cancer in Colombia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00821-X&doi=10.1016/j.jval.2022.04.620
First page :
Section Title :
Open access? :
No
Section Order :
10556